346 results on '"Schneider-Gold, Christiane"'
Search Results
2. The multiple roles of nerve biopsy in the diagnosis and prognosis of suspected immune neuropathies
3. Expertenempfehlung zur Magnetresonanztomographie bei Muskelerkrankungen
4. Weaning and extubation failure in myasthenic crisis: a multicenter analysis
5. Therapie der Myasthenie und myasthener Syndrome
6. Autorinnen und Autoren
7. Update Myasthenia gravis
8. Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells
9. Seronegative myasthenic crisis: a multicenter analysis
10. Successful Treatment of Concomitant Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome with Autologous CD19-targeted CAR-T Cells (P4-14.006)
11. Phoenix from the ashes: dramatic improvement in severe late-onset methylenetetrahydrofolate reductase (MTHFR) deficiency with a complete loss of vision
12. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy.
13. New Approaches to Critical Illness Polyneuromyopathy: High-Resolution Neuromuscular Ultrasound Characteristics and Cytokine Profiling
14. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy
15. Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy.
16. Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel
17. Kompetitive monoklonale Antikörpertherapien
18. COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis
19. Guideline for the management of myasthenic syndromes.
20. The emerging spectrum of foetal acetylcholine receptor antibody-associated disorders (FARAD)
21. Kapitel 24 - Therapie der Myasthenie und myasthener Syndrome
22. The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD).
23. Greater Cortical Thinning and Microstructural Integrity Loss in Myotonic Dystrophy Type 1 Compared to Type 2
24. Severe refractory CIDP: a case series of 10 patients treated with bortezomib
25. Vagal cross-sectional area correlates with parasympathetic dysfunction in Parkinson's disease
26. Vorteile durch Behandlung mit Rituximab im Frühstadium
27. CASQ1 mutations impair calsequestrin polymerization and cause tubular aggregate myopathy
28. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society
29. Abnorme Muskelermüdbarkeit: Was steckt dahinter?
30. Seronegative myasthenic crisis: a multicenter analysis
31. Vagal cross-sectional area correlates with parasympathetic dysfunction in Parkinson's disease.
32. Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by transcranial sonography
33. Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A prospective cohort study of different CIDP subtypes and disease stages
34. Schnelles Ausschleichen ist machbar
35. RNA Foci, CUGBP1, and ZNF9 Are the Primary Targets of the Mutant CUG and CCUG Repeats Expanded in Myotonic Dystrophies Type 1 and Type 2
36. Phoenix from the ashes: dramatic improvement in severe late-onset methylenetetrahydrofolate reductase (MTHFR) deficiency with a complete loss of vision
37. Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis
38. Report of a fulminant anti‐ pan‐neurofascin ‐associated neuropathy responsive to rituximab and bortezomib
39. COVID-19 mRNA vaccine induced rhabdomyolysis and fasciitis
40. Prevalence and characteristics of polyneuropathy in atypical Parkinsonian syndromes
41. Klinik und Transition neuromuskulärer Erkrankungen
42. SONOGRAPHIC MONITORING OF SEVERE FOCAL B-CELL MYOSITIS OF THE ANTERIOR CALF MUSCLE RESPONSIVE TO RITUXIMAB
43. Prevalence and Characteristics of Polyneuropathy in Atypical Parkinsonian Syndromes: An Explorative Study
44. Additional file 1 of Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel
45. sj-docx-1-tan-10.1177_1756286421999631 – Supplemental material for Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study
46. Additional file 3 of Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel
47. Additional file 2 of Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel
48. New approaches to critical illness polyneuromyopathy
49. GSK3β mediates muscle pathology in myotonic dystrophy
50. Evaluation of the EFNS/PNS diagnostic criteria in a cohort of CIDP patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.